Primary mediastinal B-cell lymphoma (PMBCL): The LYSA pragmatic guidelines.

Fiche publication

Date publication

mars 2025

Journal

European journal of cancer (Oxford, England : 1990)

Auteurs

Membres identifiés du Cancéropôle Est :
Pr MARTIN Laurent

Tous les auteurs :
Renaud L, Donzel M, Decroocq J, Decazes P, Galtier J, Burroni B, Veresezan EL, Sesboüé C, Dartigues P, Chassagne-Clément C, Martin L, Mauduit C, Kaltenbach S, Penther D, Etancelin P, Sibon D, Bailly S, Martin V, Durot E, Kirova Y, Grenier A, Maerevoet M, Bernard W, Naveau L, Cabannes-Hamy A, Cottereau AS, Jacquet-Francillon N, Noel R, Reichert T, Sarkozy C, Bussot L, Bailly S, Amorim S, Krzisch D, Cornillon J, Legendre H, Chevillon F, Cavalieri D, Sesques P, Minard-Colin V, Haioun C, Morschhauser F, Houot R, Jardin F, Tilly H, Traverse-Glehen A, Camus V

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/40157284

Résumé

Primary mediastinal B-cell lymphoma (PMBCL) is a distinct subtype of large B-cell lymphoma with unique clinical, histopathological, and molecular characteristics. Despite its aggressive nature, PMBCL has a high cure rate when managed appropriately. Advances in the understanding of PMBCL biological characteristics, coupled with improvements in diagnostic tools and therapeutic approaches, have significantly improved patient outcomes in recent years. In this article, we present a set of pragmatic guidelines developed by the Lymphoma Study Association (LYSA) for the management of PMBCL. These guidelines address key aspects of diagnosis, staging, response evaluation, and treatment, integrating the latest evidence from clinical trials, expert consensus, and real-world practice. The aim of the guidelines is to provide clinicians with a clear, practical framework to optimize care for patients with PMBCL, ensuring that the best available evidence is translated into clinical practice.